
Calamos' New ETFs Promise Market Exposure Without The Meltdowns
Vertex Pharmaceuticals Inc. VRTX is giving investors some good news — especially if they're keeping a close eye on its newly launched painkiller Journavx. At the 2025 Napa Valley Biotech Forum, JPMorgan analyst Jessica Fye walked away with a bullish …